Report cover image

Global High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 108 Pages
SKU # APRC20340778

Description

Summary

According to APO Research, The global High Performance Active Pharmaceutical Ingredients (HPAPI) market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for High Performance Active Pharmaceutical Ingredients (HPAPI) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for High Performance Active Pharmaceutical Ingredients (HPAPI) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for High Performance Active Pharmaceutical Ingredients (HPAPI) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of High Performance Active Pharmaceutical Ingredients (HPAPI) include BASF, Boehringer Ingelheim, Bristol-Myers Squibb, Hospira, Novasep, Sanofi Aventis, Bayer, Pfizer and Lonza, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for High Performance Active Pharmaceutical Ingredients (HPAPI), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding High Performance Active Pharmaceutical Ingredients (HPAPI).

The High Performance Active Pharmaceutical Ingredients (HPAPI) market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global High Performance Active Pharmaceutical Ingredients (HPAPI) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

High Performance Active Pharmaceutical Ingredients (HPAPI) Segment by Company

BASF
Boehringer Ingelheim
Bristol-Myers Squibb
Hospira
Novasep
Sanofi Aventis
Bayer
Pfizer
Lonza
Merck
Novartis
Teva Pharmaceuticals
High Performance Active Pharmaceutical Ingredients (HPAPI) Segment by Type

Synthetic Ingredients
Biological Ingredients
High Performance Active Pharmaceutical Ingredients (HPAPI) Segment by Application

Oncology
Cardiovascular
Glaucoma
Anti-diabetic
Musculoskeletal
Hormonal
Others
High Performance Active Pharmaceutical Ingredients (HPAPI) Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global High Performance Active Pharmaceutical Ingredients (HPAPI) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of High Performance Active Pharmaceutical Ingredients (HPAPI) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of High Performance Active Pharmaceutical Ingredients (HPAPI).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of High Performance Active Pharmaceutical Ingredients (HPAPI) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of High Performance Active Pharmaceutical Ingredients (HPAPI) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

108 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Estimates and Forecasts (2020-2031)
1.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Market by Type
1.3.1 Synthetic Ingredients
1.3.2 Biological Ingredients
1.4 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Type
1.4.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Overview by Type (2020-2031)
1.4.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Historic Market Size Review by Type (2020-2025)
1.4.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Type (2020-2025)
1.5.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Type (2020-2025)
1.5.4 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Trends
2.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Drivers
2.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Opportunities and Challenges
2.4 High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue (2020-2025)
3.2 Global Top Players by High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (2020-2025)
3.3 Global Top Players by High Performance Active Pharmaceutical Ingredients (HPAPI) Price (2020-2025)
3.4 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Major Company Production Sites & Headquarters
3.6 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Company, Product Type & Application
3.7 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market CR5 and HHI
3.8.2 Global Top 5 and 10 High Performance Active Pharmaceutical Ingredients (HPAPI) Players Market Share by Revenue in 2024
3.8.3 2023 High Performance Active Pharmaceutical Ingredients (HPAPI) Tier 1, Tier 2, and Tier 3
4 High Performance Active Pharmaceutical Ingredients (HPAPI) Regional Status and Outlook
4.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Historic Market Size by Region
4.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales in Volume by Region (2020-2025)
4.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales in Value by Region (2020-2025)
4.2.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Forecasted Market Size by Region
4.3.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales in Volume by Region (2026-2031)
4.3.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales in Value by Region (2026-2031)
4.3.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 High Performance Active Pharmaceutical Ingredients (HPAPI) by Application
5.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Market by Application
5.1.1 Oncology
5.1.2 Cardiovascular
5.1.3 Glaucoma
5.1.4 Anti-diabetic
5.1.5 Musculoskeletal
5.1.6 Hormonal
5.1.7 Others
5.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Application
5.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Overview by Application (2020-2031)
5.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Historic Market Size Review by Application (2020-2025)
5.2.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Application (2020-2025)
5.3.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Application (2020-2025)
5.3.4 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 BASF
6.1.1 BASF Comapny Information
6.1.2 BASF Business Overview
6.1.3 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.1.4 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.1.5 BASF Recent Developments
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Comapny Information
6.2.2 Boehringer Ingelheim Business Overview
6.2.3 Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Comapny Information
6.3.2 Bristol-Myers Squibb Business Overview
6.3.3 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.3.5 Bristol-Myers Squibb Recent Developments
6.4 Hospira
6.4.1 Hospira Comapny Information
6.4.2 Hospira Business Overview
6.4.3 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.4.5 Hospira Recent Developments
6.5 Novasep
6.5.1 Novasep Comapny Information
6.5.2 Novasep Business Overview
6.5.3 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.5.5 Novasep Recent Developments
6.6 Sanofi Aventis
6.6.1 Sanofi Aventis Comapny Information
6.6.2 Sanofi Aventis Business Overview
6.6.3 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.6.5 Sanofi Aventis Recent Developments
6.7 Bayer
6.7.1 Bayer Comapny Information
6.7.2 Bayer Business Overview
6.7.3 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.7.5 Bayer Recent Developments
6.8 Pfizer
6.8.1 Pfizer Comapny Information
6.8.2 Pfizer Business Overview
6.8.3 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.8.5 Pfizer Recent Developments
6.9 Lonza
6.9.1 Lonza Comapny Information
6.9.2 Lonza Business Overview
6.9.3 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.9.5 Lonza Recent Developments
6.10 Merck
6.10.1 Merck Comapny Information
6.10.2 Merck Business Overview
6.10.3 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.10.5 Merck Recent Developments
6.11 Novartis
6.11.1 Novartis Comapny Information
6.11.2 Novartis Business Overview
6.11.3 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.11.5 Novartis Recent Developments
6.12 Teva Pharmaceuticals
6.12.1 Teva Pharmaceuticals Comapny Information
6.12.2 Teva Pharmaceuticals Business Overview
6.12.3 Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.12.5 Teva Pharmaceuticals Recent Developments
7 North America by Country
7.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
7.1.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2020-2025)
7.1.3 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2026-2031)
7.2 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country
7.2.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country (2020-2025)
7.2.3 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
8.1.1 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2020-2025)
8.1.3 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2026-2031)
8.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country
8.2.1 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country (2020-2025)
8.2.3 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
9.1.1 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2020-2025)
9.1.3 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country
9.2.1 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country (2020-2025)
9.2.3 Asia-Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
10.1.1 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2020-2025)
10.1.3 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2026-2031)
10.2 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country
10.2.1 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country (2020-2025)
10.2.3 South America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
11.1.1 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2020-2025)
11.1.3 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country
11.2.1 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country (2020-2025)
11.2.3 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Value Chain Analysis
12.1.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 High Performance Active Pharmaceutical Ingredients (HPAPI) Production Mode & Process
12.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Distributors
12.2.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.